个股公告正文
新产业：华泰联合证券有限责任公司关于公司首次公开发行股票并在创业板上市发行保荐书
日期：2020-04-20附件下载
1
10A
15A+H IPO A IPOIPO A IPO
IPO IPO IPO
IPO A IPO IPO
2
1
2 23
3 1995 12 15
4 2012 8 23
5 37,040
6
7 0755-86540062
82002 452
6823
6824 6825 6828 6830
X 6840 6840 6854
[ 021738 ] 6840
6840 [
20000003
]
9
1
2016 3 6
2
2016 3 7 -11
2016 3 14
2016 3 18
3
4
2016 3 23
3
2016 3 23
2016 12
5
2/3
2/3
5
2016 3 23 2016 12
A2012 3 5
911101085923425568
19 68 A-1 A-5
,
,
(
PUE 1.4 )
100048
8610-88827799
8610-88018737
tzcpa@tzcpa.com
20.00
33
1 2016 3 3
7 7
A
A
A
2 2016 3 24 2015
370,400,000 100%
A
A
A
3 2018 3 3
7 7
A
A
4 2018 3 23 2017
369,420,800 99.74%
A
A
5 2019 2 25
7 7
A
A
6 2019 3 18 2018
A
A
7 2020 2 14
7 7
A
A
8 2020 3 5 2019
A
A
2019
2020 3 24 12
2017 53,820.68 2018
69,399.68 2019 77,260.90
3,000
4,120
41,160 10%
1
1
2
3
4
1 2012 8 23
1995 12 15
[2012]094
[2012]0150 [2012]0150
[2014]002
2[2019]001606 [2020]000935 2017 20182019 50,066.51
64,126.23 71,770.73 2017 2018 2019
114,056.47 138,361.10 168,158.81
3 [2019]001606
[2020]000935 2019 12 31 313,879.32
234,399.68
4 37,040
4,120
3,000
2
3
4
5
6
7
[2020]000935
8
[2020]000891
9
1
2
3
10
2012
1
2
3
4 PE PE
,
5
,
6
7
8
9
10
11
121 SD1420 P1000645
2 SL7271 P1001079
3 SD2055 P1000740
4 SD6213 P1002037
5 S80000 P1018323
6 SD2876 P1002046
7 SD4964 P1000970
8 SD1403 P1000481
9 SE5137 P1000481
10 S22067 P1000481
11 S81123 P1000481
12 SD3421 P1002059
13 S86090 P1002059
1
2
3
2016 4 2016
2016 11 8
1
2017 2018 2019
95.81% 95.30% 95.16%
2
3
95.20% 94.91% 95.34%
2017 1,800 2019 2,300
4
1
2
CE FDA
5
114,056.47 138,361.10
168,158.81 2017 1,367 2019 1,760
6
2019
358 5%
1
2
143 2017 2018 2019
22,453.22 26,634.80 34,261.86
19.69% 19.25% 20.39%
3
143
ISO9001 ISO13485 CE
FDA
MAGLUMI2000 5
TSH T3 T4
FT3 FT4 25- D 25-OH Vitamin
D HCG
NMPA
2019 47.34%
21.06% 16.72% 13.42%
2020 1
1
2
2019 30
3
2
2020 2 3
2020 3 31
100%
3
2019
20.39% 2% 2019 20
2020 1-2 2020 3
2020 3
33.39% 2020107%
2020 3
1
2
3
1
15% 2012
9 2012 -2014
15% 2015 11
2018 10
25%
2
[2009]9
2010 6
[2006]0015[2011]0324
6% 2014 6 13
[2014]57 2014 7 1 6% 3% 2018 4
4
[2018]32 2018 5 1
17% 11% 16% 10% 2019 3
30
2019 39 2019 4 1
16% 10%
13% 9%
[2011]100 17%
3%
15%
3
14,308.66 19,441.20
23,677.30 7.08% 7.36% 6.85%
1.84 1.57 1.56
4
21,281.71 24,163.43
27,654.80 2018 2017 13.54% 2019 2018
14.45%5
31.68% 31.24% 26.07%
6
19.69% 19.25% 20.39%
2017 2018 2019
1,313.96 -2,019.03 -751.66
7
78.67% 80.81% 79.96%
8
2,457.05
2,808.92 2,381.31 3.90% 3.48%
2.65%
114,056.47 138,361.10
168,158.81 53,820.68 69,399.68 77,260.90
1
3,000 1,500400
2
3
4
2019 12 31
1 2020
2020 1-3 2020 1-3
28,875.27 8.37%
11,074.96 19.77%
9,618.47 22.10%
2020 1-3 2019 1
33.39% 2 2019
2020
67.38% 3 2020
2019 2020
234.69%
2 2020
3
2020 59,000 62,000
16.24% 20.29% 2020 3
2020
2020
2020 26,000
27,500 18.74% 23.18%
23,000 25,000 19.67% 26.09%
20201
2018 650 2018 2023
4% 2023 778 1
2016-2021
Kalorama Information, The Worldwide Market for In Vitro Diagnostic IVD Tests,
10th Edition
2018 64%2
1 Karorama Information , The Worldwide Market for In Vitro Diagnostic Tests, 11 Edition
2Kalorama Information, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 11th Edition
1-2% 3
2018
Kalorama Information, The Worldwide Market for In Vitro Diagnostic IVD Tests,
11th Edition
10%
15% 4
3Kalorama Information, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition
4 Kalorama Information, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition
2015-2019
2015-2019 EMEA
2016
Kalorama Information, The Worldwide Market for In Vitro Diagnostic IVD Tests,
10th Edition
2
Allied Market Research 2016 410
Allied Market ResearchAllied Market Research
20%1
2018
18%5 106 6
5
6 Allied Market Research
2
A
RIA 70
ELISA 70
EL1SA
TRFIA
CLIA RIA
ELISA MAIA
HRP
90%
1 E 6 HA,LN,PCIII,CIV,FN
E2 7
AFP,CEA,PSA,FPSA,FER,CA199,CA125,CA AOA,AEA,ASA,ATB.ACA.ZB,HCG
-3 8
LH,FSH,TSH,E2,PRO,PRL,TES,HCG,B-HCG TOX,CMV,HSVI,HSVII,RUB
4 9 ALB,
5 10
C INS,INS-
B
2010
1
20
2008
MAGLUMI2000
68
MAGLUMI 2000 PLUS MAGLUMI 1000 MAGLUMI 600 MAGLUMI
4000 MAGLUMI 800 MAGLUMI 4000 Plus MAGLUMI X8
McEvoy & Farmer 2015
2015 1.8%
2
1
0.5
20%~60%
2
600 /
10 30
3
ABEI
ABEI
ABEI
ABEI
150
EB
122
4
EB TORCH
1
1 -
2
276D ABEI
3
MAGLUMI 2000PLUS MAGLUMI 4000 MAGLUMI
600 MAGLUMI 800 MAGLUMI 4000 Plus MAGLUMI X8
4 RFID
5
2019 12 31 150
49 69 32
19 2020 3 31 172
2
1
MAGLUMI2000
MAGLUMIMALGUMI X8 600 /
Biossays 1200 Biossays
2200 Biossays 2200 1600 /
MALGUMI X8 MAGLUMI 4000 PlusBiossays 240 Biossays 240 Plus Biossays1200 Biossays 2200 Biossays C8 240 / 1600
/
Biolumi 8000 2019RFID
4 3
122 122
Lp-PLA2 I 25-OH VD
CA50 CA72-4 CA24-2 Cyfra21-1 SCCA TRAb rT3
2020 3 31 31
/ IgG LSSc
/ M2-3E IgG PBC
IgG SLE
/
/ IgG SLE
/
1
/
/
/
/
Sm/RNP IgG SLE
/ MCTD
/ Sm IgG
(SS)
/ SS-A/Ro IgG SLE
C2 C4
(SS)
/ SS-B IgG SLE
/ Jo-1 IgG /
(PM/DM)
/
/ e
/ e
/
/ IgG I
/ Ferene
/ / /
/
/
/ - -
/ C
/
/ RA
/
/ -L- CNPF
/
/ NBT
2020 3 31 7
/ IgG
/ 2
/ IgM
/
/ A
/
IgG Wegener WG
/
2
20
3
8 122
1
122
2
3
4
6,800
2019 12 31
112 238 88 424
158 321 27 510
287 481 82 670
109 194 26 235
81 145 17 172
67 221 28 273
93 248 52 491
907 1,848 320 2,775
5
48 2019 12 31
383
15
6
4
8
7
10
13
1
2
9
2
2
5
4
6
3
2
5
9
113
6
1
2
1
3 1 2 3
3
3
3 1 1
2
3
3
3
2
1
2020 3 31 8 122
2020
3 31 4 39
600 /
15 300
MAGLUMI 42
1 X8 24
,
280 /
MAGLUMI 16 144
4000 Plus 24 25
2
,
MAGLUMI 280 / 144
4000 15 25
3
24
MAGLUMI 180 / 144
2000Plus 17 25
4
24
MAGLUMI 180 / 144
2000 17 15
5
24
MAGLUMI 120 / 144
1000 17 15
6
24
MAGLUMI 180 / 40 9
800 17
7
24
MAGLUMI 180 / 16 4
600 17
8
24
Biossays 90
BC1200 900 / 115
1
0-3.0Abs
1600 /
Biossays 280 90
BC2200 4
2
6400
/
0-3.0Abs
240 /
45 90
Biossays 0-3.2Abs
3 240 88
200 /
Biossays 240 / 45 90
4 240Plus 88
0-3.2Abs
200 /
1 12
2 11
3 7 I II
4 2
5 5
/
6 19 /
7 4 VD
8 3
9 4
10 3
/
11 13
12 3
13 3
14 8
15 9
16 EB 6
SLE RA
17 4 MCTD SS
SSc
18 6
1 9
2 6
3 2
4 9 /
5 4
6 4
7 1
8 3
9 1
1
2
5,800
143
2
2019 2018 2017
27,424.71 16.32% 22,699.64 16.41% 23,642.23 20.73%
132,439.20 78.83% 109,156.80 78.89% 85,631.11 75.08%
8,135.84 4.84% 6,504.66 4.70% 4,783.14 4.19%
167,999.75 100.00% 138,361.10 100.00% 114,056.47 100.00%
1995
2005
2008
2010
20
